

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2004/012075
International Filing Date : 26 October 2004 (26.10.2004)
Priority Date(s) Claimed : 20 November 2003 (20.11.2003)
Applicant(s) (DO/EO/US) : Gerard MOINET, et al.

Title: ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND
BENZOTHIOPHENE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- ☒ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - ☒ within three months of the actual filing date of the national phase of a PCT application; OR
 - ☐ before the mailing of a first substantive office action (including after filing of an RCE).
- ☐ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- a final rejection under 37 C.F.R. 1.113;
 - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2); OR
 - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
- ☐ a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

☐ Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:

- ☐ a final action under 37 C.F.R. § 1.113;
- ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
- ☐ OR a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- ☐ Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- ☒ Copies of materials listed but not attached were cited in an international search report dated February 28, 2005.
- ☐ Not required by 37 CFR § 1.98.
- ☐ Copies of the materials listed are attached (except for the foregoing).

Non-English Language References

- ☒ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
- ☐ A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
- X = document of particular relevance when it is taken alone
Y = document of particular relevance when it is combined with another such document
A = document defining the general state of the art
O = non-written disclosure
P = intercalated document
T = document cited to understand the theory or principle underlying the invention
E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
D = cited in the application
L = cited for another reason
& = publication of member of same patent family
- ☐ Translation of other relevant information on foreign search report

Other Information


Payment of Fees Due (If Any):

- ☐ A check for \$_____ covering the fee identified above is attached.
- ☐ Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

IAP12 Rec'd PCT/PTO 19 MAY 2006

☒ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3172

Date: May 19, 2006

AJZ:ssr

IAP12 Rec'd PCT/PTO 19 MAY 2006

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.			
Substitute for form 1449A/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
<i>(use as many sheets as necessary)</i>			
Sheet	1	of	3

Complete if Known	
Application Number	USNP of PCT/EP2004/012075
Filing Date	26 October 2004 (26.10.2004)
First Named Inventor	Gerard MOINET, et al.
Group Art Unit	unknown
Examiner Name	unknown
Attorney Docket Number	MERCK-3172

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	USNP of PCT/EP2004/012075
				Filing Date	26 October 2004 (26.10.2004)
				First Named Inventor	Gerard MOINET, et al.
				Group Art Unit	unknown
				Examiner Name	unknown
Sheet	2	of	3	Attorney Docket Number	MERCK-3172

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	004	DARIAS, V. ET AL: "BICYCLIC THIOPHENIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS" FARMACO, EDIZIONE SCIENTIFICA, 41(6), 478-82 CODEN: FRPSAX; ISSN: 0430-0920, 1986, XP001194422		
	005	CONDE, SANTIAGO ET AL.: "ANALOGS OF PROPRANOLOL. SYNTHESIS OF 3-ALKYLAMINO-1-(3-BENZO ^b ITHIENYLOXY)-2-PROPANOLS" JOURNAL OF HETEROCYCLIC CHEMISTRY, 17(5), 937-40 CODEN: JHTCAD; ISSN: 0022-152X, 1980, XP002286806		
	006	WITIAK, DONALD T. ET AL: "9-CHLORO-2, 3-DIHYDRO-5H-1, 4-DIOXEPINO '6,5-b ¹ BENZOFURAN, A NOVEL ANTILIPIDEMIC AGENT STRUCTURALLY RELATED TO CLOFIBRATE" JOURNAL OF MEDICINAL CHEMISTRY, 18(10), 992-6 CODEN: JMCMAR; ISSN: 0022-2623, 1975, XP002286807		
	007	CONNOR, DAVID T. ET AL: "NOVEL BENZOTHIOPHENE-, BENZOFURAN-, AND NAPHTHALENECARBOXAMIDOTETRAZOLES AS POTENTIAL ANTIALLERGY AGENTS" JOURNAL OF MEDICINAL CHEMISTRY, 35(5), 958-65 CODEN: JMCMAR; ISSN: 0022-2623, 1992, XP002286756		
	008	TONDEUR, R. ET AL: "BENZOFURAN SERIES XXXV. AMINO DERIVATIVES OF 3-BENZOFURANOL" CHIMICA THERAPEUTICA, 3(5), 356-9 CODEN: CHTPBA; ISSN: 0009-4374, 1968, XP009033121		
	009	SVOBODA, JIRI ET AL.: "SYNTHESIS OF '1BENZOTHIENO'3,2-b ¹ IFURAN-A NEW FUSED BENZOHETEROCYCLIC SYSTEM: COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 58(12), 2983-6 CODEN: CCCCCK; ISSN: 0010-0765, 1993, XP009033071		
	010	VAIDYA, V. P. ET AL: "STUDIES IN BENZOFURANS: PART XIV. SYNTHESIS OF BENZOFURAN AND BENZOFURO'3,2-b ¹ IFURAN DERIVATIVES OF PHARMACOLOGICAL INTEREST" INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, 22B(5), 462-4 CODEN: IJSBDB; ISSN: 0376-4699, 1983, XP009033083		
	011	KARCHE, NAVNATH P. ET AL: "ELECTRONIC EFFECTS IN MIGRATORY GROUPS. '1,4I-VERSUS '1,2I-REARRANGEMENT IN RHODIUM CARBENOID GENERATED BICYCLIC OXONIUM YLIDES" JOURNAL OF ORGANIC CHEMISTRY, 66(19), 6323-6332 CODEN: JOCEAH; ISSN: 0022-3263, 2001, XP002286808		
	012	BOSCHELLI, DIANE ET AL: "INHIBITION OF E-SELECTIN-, ICAM-1-, AND VCAM-1-MEDIATED CELL ADHESION BY BENZO ^b ITHIOPHENE-, BENZOFURAN-, INDOLE-, AND NAPHTHALENE-2-CARBOXAMIDES: IDENTIFICATION OF PD 144795 AS AN ANTIINFLAMMATORY AGENT" JOURNAL OF MEDICINAL CHEMISTRY, 38(22), 4597-614 CODEN: JMCMAR; ISSN: 0022-2623, 1995, XP002286757		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	USNP of PCT/EP2004/012075
				Filing Date	26 October 2004 (26.10.2004)
				First Named Inventor	Gerard MOINET, et al.
				Group Art Unit	unknown
				Examiner Name	unknown
				Attorney Docket Number	MERCK-3172
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	013	BOSCHELLI, DIANE ET AL: "3-ALKOXYBENZO'BITHIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF NEUTROPHIL-ENDOTHELIAL CELL ADHESION" JOURNAL OF MEDICINAL CHEMISTRY, 37(6), 717-18 CODEN: JMCMAR; ISSN: 0022-2623, 1994, XP002286755	
	014	SVOBODA, JIRI ET AL: "APPLICATION OF MAGNESIUM ALKOXIDES TO SYNTHESSES OF BENZOHETEROCYCLIC COMPOUNDS" COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 58(3), 592-9 CODEN: CCCCCK; ISSN: 0010-0765, 1993, XP001194423	
	015	NORRIS, ROBERT ET AL: "SOME STUDIES ON THE REVERSIBILITY OF THE ASSOCIATION STEP IN SRN1 REACTIONS: AUSTRALIAN JOURNAL OF CHEMISTRY, 38(7), 1107-16 CODEN: AJCHAS; ISSN: 0004-9425, 1985, XP009033098	
	016	BECK JAMES: "1!BENZOTHIENO'3,2-b!FURAN DERIVATIVES" JOURNAL OF HETEROCYCLIC CHEMISTRY, 12 (5), 1037-8 CODEN: JHTCAD; ISSN: 0022-152X, 1975, XP002286809	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.